Our previous work showed that this BBB-penetrating TNF-α inhibitor reduces Aβ plaques, insoluble Aβ1-42, BBB-disruption, brain endothelial activation, and cognitive memory deficits in the APP/PS1 double transgenic AD mouse model of amyloidosis [37]. This evidence concerns the gene APP and amyloidosis.